Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

Part of paid clinical trials in West Hollywood, California.

Sponsor
Acorn Biolabs Inc.
Study ID
NCT07107841
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Autologous Hair Follicle-Derived Secretome — OTHER
    Hair follicles are plucked, cultured and the product is the resulting cell secretions (secretome) collected from the conditioned media.
  • Placebo Control — OTHER
    The same saline used for diluting the active treatment in will be used as a control.

Study Details

(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.

Key Dates

Start date
Oct 16, 2025
Status verified
Feb 2026
Primary completion
Sep 15, 2027
Completion
Sep 15, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Active-Secretome
    Intervention is autologous hair follicle-derived secretome diluted in saline
  • Placebo Comparator: Placebo Control
    Placebo control is saline.

Primary Outcome Measure

Target Area Hair Counts (TAHC) [ Time Frame: 180 Days after Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ziering MedicalWest HollywoodCalifornia90069
Craig Ziering, MD
[email protected]
310-360-8860

Find similar trials in West Hollywood, CA

By research site
Ziering Medical· West Hollywood, CA

Related Studies